|Dr. Michael R. Bristow M.D., Ph.D.||Co-Founder, Chief Exec. Officer, Pres and Director||402.56k||N/A||72|
|Mr. Thomas A. Keuer||Chief Operating Officer||365.83k||N/A||58|
|Mr. Christopher D. Ozeroff||Sr. VP, Gen. Counsel and Sec.||346.87k||N/A||58|
|Mr. Brian L. Selby||Chief Accounting Officer and VP of Fin.||N/A||N/A||55|
|Monique Plamondon||VP of Regulatory Affairs & QA||N/A||N/A||N/A|
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
ARCA biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.